EN DE
Watch Alaunos Therapeutics, Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Alaunos Therapeutics, Inc (TCRT) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Alaunos Therapeutics, Inc stock $0.75, price $1.59, that is 52.8% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US98973P1012

AT Alaunos Therapeutics, Inc logo Thin data Nov 16, 2026

Alaunos Therapeutics, Inc

TCRT · US

Far too expensive (fair value 53% below the price), weak company and price moving sideways: meets none of the 3 rules.

Follow free in the weekly email
Price moving sideways (no uptrend) 
Revenue last quarter 25% below a year ago. 
Fair value $0.75 · Strongly overvalued 
Quality 29/100 
Weak Growth (revenue 3y −88.0 %/yr in USD) 
Negative free cash flow 
Trails peers (1/7) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Alaunos Therapeutics, Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$553.50 $0.74 Fair Value $0.75 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $0.74 – $553.50 · fair‑value band $0.56 – $0.94 · the $1.59 price screens above the $0.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Alaunos Therapeutics in your weekly email

Every Wednesday you see whether Alaunos Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders.

Show moreShow less

It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Stock analysis

Alaunos Therapeutics, Inc (TCRT) currently trades at $1.59, while our estimate is $0.75, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.56 (bear) to $0.94 (bull), the price of $1.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Alaunos Therapeutics, Inc reported revenue of $5.0K in FY2025 versus $398K in FY2021, a compound −66.5%/yr. Reported net income was −$4.2M in FY2025.

Key figures

Market cap $6.8M Micro · EPS (TTM) $-1.76 · Return on equity −186% · Return on assets (EBIT) −174% (5-year average) · Operating margin −135,233% · Revenue (TTM) $3.0K · Revenue growth (YoY) −25.0% · Free cash flow −$3.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 64% below its 52-week high and 115% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −53%, TCRT screens richer than that median.

Fair Value

Bear $0.56 Fair Value $0.75 Bull $0.94
Price $1.59 · Downside -52.8%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 19, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−50.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−88.0%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−19,484.7% (2021) → −84,500.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TCRT screens overvalued: fair value 53% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Alaunos Therapeutics, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 852 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −52.8% · Bottom 25%
Profitability
Return on assets −140.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −25.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.17× · Pricier than median
PEG 0.58× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $923.34 $1,275.02 +38% vs TCRT
Vertex Pharmaceuticals Incorporated VRTX $520.66 $587.62 +13% vs TCRT
Samsung Biologics Co 207940 ₩1,355,000 ₩1,512,500 +12% vs TCRT
argenx SE ARGX $942.04 $908.40 −4% vs TCRT
CSL Limited CSL A$197.29 A$188.80 −4% vs TCRT
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs TCRT
Moderna, Inc MRNA $199.33 $122.98 −38% vs TCRT
Revolution Medicines, Inc RVMD $159.43 $83.12 −48% vs TCRT
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs TCRT
Royalty Pharma plc RPRX $67.72 $19.01 −72% vs TCRT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alaunos Therapeutics, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Alaunos Therapeutics, Inc Fair Value". https://www.fairvalue-calculator.com/stock/TCRT

Frequently asked questions

Is Alaunos Therapeutics, Inc (TCRT) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $0.75 versus a price of $1.59, about 53% lower (overvalued).
What is the fair value of TCRT?
Our estimate for Alaunos Therapeutics, Inc is $0.75 (as of Nov 16, 2026), built from audited fundamentals. The current price: $1.59.
What is the quality score of TCRT?
Alaunos Therapeutics, Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alaunos Therapeutics, Inc (TCRT)?
We do not set a price target; the yardstick is our estimate of $0.75 (as of Nov 16, 2026). Cautious scenario $0.56, optimistic scenario $0.94. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Alaunos Therapeutics, Inc stock forecast for 2026?
Our estimate puts fair value at $0.75, about 53% lower versus a price of $1.59 (overvalued). Cautious scenario $0.56, optimistic scenario $0.94. The calculation is refreshed regularly with new filings.
What is the revenue of Alaunos Therapeutics, Inc (TCRT)?
Alaunos Therapeutics, Inc reported trailing-twelve-month revenue of about $3.0K (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Alaunos Therapeutics, Inc (TCRT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alaunos Therapeutics, Inc it is $0.75 per share (as of Nov 16, 2026), against a price of $1.59.
Is Alaunos Therapeutics, Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, TCRT trades above its calculated fair value: price $1.59, fair value $0.75, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TCRT?
No. The price is what the market pays today ($1.59); the fair value is what the company's own numbers justify ($0.75). For Alaunos Therapeutics, Inc the two are $0.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alaunos Therapeutics, Inc worth?
The market values Alaunos Therapeutics, Inc at about $6.8M (market capitalisation, as of Nov 16, 2026). Per share that is $1.59; our models calculate a fair value of $0.75 per share.
What do the bullish and bearish scenarios say about TCRT?
Our models span a range for Alaunos Therapeutics, Inc: cautious scenario $0.56, base $0.75, optimistic $0.94 per share (as of Nov 16, 2026, price $1.59). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of TCRT?
The PEG ratio of Alaunos Therapeutics, Inc is 0.58 (P/E divided by earnings growth, as of Nov 16, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Alaunos Therapeutics, Inc (TCRT)?
Balance-sheet figures for Alaunos Therapeutics, Inc (as of Nov 16, 2026): return on equity −186.0%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is TCRT from its 52-week high?
Alaunos Therapeutics, Inc trades at $1.59, about 64% below its 52-week high of $4.36 and 115% above the low of $0.74 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of $0.75 is for.
Which stocks are comparable to Alaunos Therapeutics, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alaunos Therapeutics, Inc stock attractive at the current price?
The data as of Nov 16, 2026: price $1.59, calculated fair value $0.75 (−53%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Alaunos Therapeutics, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alaunos Therapeutics, Inc (TCRT)?
The closing price on Nov 19, 2026 was $1.59. Our estimate is $0.75, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alaunos Therapeutics, Inc right now?
The price sits above even our optimistic bull case ($0.94). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Alaunos Therapeutics, Inc

How large is the market capitalisation of Alaunos Therapeutics, Inc (TCRT)?
The market capitalisation of Alaunos Therapeutics, Inc is $6.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Alaunos Therapeutics, Inc (TCRT)?
Earnings per share at Alaunos Therapeutics, Inc are $-1.76. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Alaunos Therapeutics, Inc (TCRT)?
The return on equity (ROE) of Alaunos Therapeutics, Inc is −186% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alaunos Therapeutics, Inc (TCRT)?
On an EBIT basis the return on assets of Alaunos Therapeutics, Inc is −174% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alaunos Therapeutics, Inc (TCRT)?
The operating margin of Alaunos Therapeutics, Inc is −135,233% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alaunos Therapeutics, Inc (TCRT)?
Revenue at Alaunos Therapeutics, Inc is down 25.0% versus a year earlier (3y avg −88.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Alaunos Therapeutics, Inc (TCRT) generate?
The free cash flow of Alaunos Therapeutics, Inc is −$3.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Alaunos Therapeutics, Inc (TCRT) hold?
Alaunos Therapeutics, Inc holds more cash than debt, $1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Alaunos Therapeutics, Inc in the live analysis

One click puts Alaunos Therapeutics, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.